Trials / Recruiting
RecruitingNCT07123103
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
A Dose Escalation and Expansion Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Exelixis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XB371 | Intravenous (IV) infusion. |
Timeline
- Start date
- 2025-08-18
- Primary completion
- 2027-11-01
- Completion
- 2028-02-01
- First posted
- 2025-08-14
- Last updated
- 2026-02-17
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07123103. Inclusion in this directory is not an endorsement.